Entera Bio vs Inmune Bio
ENTX and INMB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENTX and INMB compare
Entera Bio is the larger company, worth 18 times as much as Inmune Bio ($538M against $29.1M).
Entera Bio scores higher on the StockData Score (8 against 6 for Inmune Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENTX | INMB |
|---|---|---|
| Size and price | ||
| Market cap | $538M | $29.1M |
| Share price | $3.11 | $1.05 |
| Change, 1 year | 6.9% | −30.9% |
| Change, 5 years | −11.6% | −92.1% |
| Beta (5Y) | 0.62 | 1.32 |
| Employees | 20 | 6 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 2.0× | 1.6× (better) |
| FCF yield | −2.9% | – |
| Growth | ||
| Revenue growth (TTM) | −100% | – |
| Revenue growth, 5Y average | −35.1% | 35.4% (better) |
| EPS growth, 5Y average | −17.9% | – |
| Profitability | ||
| Return on equity | −20.3% (better) | −76.7% |
| Return on invested capital | −193% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 128.41 (better) | 6.41 |
| Altman Z-score | 117.35 (better) | −11.10 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 6.2% | 15.7% |
| Held by insiders | 11.3% | 16.7% |
| Insider net buying, 12 months | $141K | – |
| Short interest, % of float | 4.6% | 11.5% |
Go deeper
- ENTX stock overview
- ENTX income statement
- ENTX valuation and score
- INMB stock overview
- INMB income statement
- INMB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.